Accueil・Liste d'Actions・Glaukos Corp

Glaukos Corp

Fermé

SecteurSoins de santé

189.07 2.94

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

182.37

Max

185.8

Chiffres clés
By Trading Economics
Revenu	1.4M -18M
Ventes	35M 186M
BPA	-0.14
Marge bénéficiaire	-9.901
Employés	1,094
EBITDA	-1.6M -6.9M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+2.24% upside

Dividendes
By Acuity
Prochains Résultats	28 oct. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	2B 11B
Ouverture précédente	186.13
Clôture précédente	189.07

Sentiment de l'Actualité

By Acuity

43%

57%

142 / 340 Classement par Healthcare

Glaukos Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 août 2026, 19:46 UTC

Glaukos Corp. shares are lower today, reaching a session low amid broader market declines following a surprise drop in U.S. retail sales for July.

13 août 2026, 19:22 UTC

Glaukos Corp. shares are higher today amid unusually high trading volume. The stock remains significantly above its 20-day moving average.

12 août 2026, 19:16 UTC

Glaukos Corp shares are higher today, supported by overall strength in U.S. stocks and positive quarterly results from AI sector companies.

10 août 2026, 20:06 UTC

Glaukos Corp shares are higher today, following a broader market trend since Friday. Earlier, the stock reached a session high before pulling back.

7 août 2026, 20:02 UTC

Glaukos Corp shares are rising in Friday's session, supported by unusually high trading volume and a steady upward trend since Thursday's close.

4 août 2026, 19:36 UTC

Glaukos Corp shares are lower today, impacted by declines in the Health Care Equipment sub-sector. The stock pulled back after reaching an earlier high.

3 août 2026, 20:06 UTC

Glaukos Corp shares are higher amid positive market sentiment, with the S&P 500 and Nasdaq 100 also gaining. The stock remains above its 20-day moving average.

31 juil. 2026, 19:45 UTC

News

Glaukos shares are lower today despite H.C. Wainwright raising the price target to $195 from $168. Trading volume has been unusually high.

30 juil. 2026, 21:31 UTC

News

Glaukos Corp shares are lower in after-market trading, tracking declines in the Health Care Equipment sector. UBS raised its price target to $172.

29 juil. 2026, 21:22 UTC

Social Media

News

Glaukos Corp reported record net sales of $185.6 million in Q2 2026, raising its full-year revenue guidance to $680 million to $700 million. Shares are higher in after-market trading.

28 juil. 2026, 17:46 UTC

News

Glaukos Corp shares are lower after UBS initiated coverage with a Neutral rating, overshadowing Stifel's Buy rating and $175 price target.

27 juil. 2026, 19:16 UTC

Glaukos Corp shares are lower today, despite an initial gain. Broader market trends are affected by a significant drop in oil prices.

24 juil. 2026, 19:56 UTC

Glaukos Corp. shares are trading higher today, maintaining a cumulative gain since Thursday and remaining above their 20-day moving average.

21 juil. 2026, 17:41 UTC

Glaukos Corp shares are lower today amid a decline in the Health Care Equipment sub-sector, reversing the recent trend of higher daily closes.

Comparaison

Variation de prix

Glaukos Corp prévision

Objectif de Prix

By TipRanks

2.24% hausse

Prévisions sur 12 Mois

Moyen 189.77 USD 2.24%

Haut 225 USD

Bas 153 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

142 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.